About Acomplia Online
Acomplia is the newest product in weight loss for those outside the US. Residents of the US must wait on FDA approval...How does it work? It works by blocking endogenous cannabinoid binding to neuronal CB1 receptors. Activation of these receptors by endoegenous cannabinoids, such as anadamide, increases appetite. It is the most advanced endocannabinoid receptor antagonist in clinical development and offers a novel therapeutic approach to appetite control and weight reduction. Filed for approval with the FDA in April 2005, it has encountered significant delays over the past two years. In February 2007, the company learnt that the FDA had extended their decision on whether or not to approve Acomplia by a further 3 months. Despite the repeated setbacks, analysts remain optimistic that it will eventually be approved in the US as an aid to weight loss. Acomplia (Rimonabant) Cannibis Connection? Rimonabant developed from the knowledge that cannabis smokers often experience extreme hunger pangs, which cannabis smokers refer to as 'the munchies'. Acomplia works on the premise that if cannabinoids stimulate appetite, blocking cannabinoid receptors in the brain might reduce appetite.The central cannabinoid (CB1) receptors are believed to play a role in controlling food consumption and the phenomena of dependence or habit. Acomplia (Rimonabant) emerged from this researched process as a potent CB1 receptor antagonist. Preclinical animal studies subsequently showed that it could reduce consumption of fats and sugars, which contribute to weight gain.Trials involving over 6,000 obese subjects that were carried out in both the US and Europe, showed that overweight and obese patients taking Acomplia (Rimonabant) achieved significant reductions in body weight, and waist circumference (an indicator of abdominal obesity).We feel in the prevailing market there is a clear opportunity for an effective and well-tolerated anti-obesity drug.